379270-35-6

Basic information

• Product Name: [[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-, Monophenylester
• Synonyms: [[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-, Monophenylester;Tenofovir Related Compound 2;phenyl ((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate;GS7340 impurity1;GS7340 intermediate 1;phenylydrogen((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl) phosphonate;phenyl hydrogen (R)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)phosphonate;Phenyl hydrogen ({[(2R)-1-(6-amino-9H-purin-9-yl)-2-propanyl]oxy}methyl)phosphonate
• CAS NO: 379270-35-6
• Molecular Formula: C₁₅H₁₈N₅O₄P
• Molecular Weight: 363.308281
• EINECS: -0
• Product Categories: Intermediate
• Mol File: 379270-35-6.mol
• Article Data: 56

Chemical Properties

• Boiling Point: 610.1±65.0 °C(Predicted)
• Appearance: /
• Density: 1.53±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Aqueous Acid (Slightly), DMSO (Slightly, Heated, Sonicated)
• PKA: 2.09±0.10(Predicted)
• CAS DataBase Reference: [[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-, Monophenylester(CAS DataBase Reference)
• NIST Chemistry Reference: [[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-, Monophenylester(379270-35-6)
• EPA Substance Registry System: [[(1R)-2-(6-aMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-, Monophenylester(379270-35-6)

Safety Data

• Hazardous Substances Data: 379270-35-6(Hazardous Substances Data)

Usage

Appearance

White powder

Uses

[[(1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]monophenylester is an antiviral agent and a Tenofovir (T018500) intermediate. Tenofovir is an acyclic phosphonate nucleotide analogue and reverse transcriptase inhibitor, used as an anti-HIV agent.

Application

[[(1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]monophenylester is an antiviral agent and a Tenofovir intermediate. Tenofovir is an acyclic phosphonate nucleotide analogue and reverse transcriptase inhibitor, used as an anti-HIV agent.

Upstream product

• 101-02-0 triphenyl phosphite 
• 147127-20-6 tenofovir 
• 1529-17-5 phenyltrimethylsilyl ether 
• 108-95-2 phenol 
• 342631-41-8 9-[(R)-2-[[(S)-[bis(phenoxy)phosphinyl]]methoxy]propyl]adenine 
• 147127-19-3 (S)-9-(2-phosphonylmethoxypropyl)adenine 
• 62613-15-4 diphenyl iodoniumarsenic hexafluoride 
• 58109-40-3 diphenyliodonium hexafluorophosphate 
• 66003-76-7 Diphenyliodonium triflate 
• 1483-73-4 diphenyliodonium bromide 
• 322-23-6 Diphenyliodonium fluoride 
• 722-56-5 diphenyliodonium nitrate 
• 4712-55-4 diphenyl hydrogen phosphite 

Downstream Products

• 2053424-88-5 (2S)-isopropyl2-((((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate 
• 379270-37-8 (S)-isopropyl-2-(((S)-((((R)-1-(6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl)(phenoxy)phosphoryl)amino)propanoate 

Relevant articles and documents

Preparation method of tenofovir alafenamide intermediate

The invention belongs to the technical field of medicinal chemistry, and provides a preparation method of a tenofovir alafenamide intermediate. The method comprises the following steps: reacting tenofovir serving as a raw material with an alkali or an salt of an alkali metal to a generate tenofovir alkali metal single salt, and reacting the tenofovir alkali metal single salt with triphenyl phosphite to generate a target intermediate. According to the invention, the method has the advantages of simple reaction conditions, high raw material utilization degree, high yield, high purity, reductionof the use of a large amount of organic bases, less generated waste liquid, small environmental pollution, and suitableness for industrial production.

Industrial synthesis method of propofovir disoproxil fumarate

The invention provides a preparation process of propofovir disoproxil fumarate, which is short in production period, simple to operate and suitable for industrial production, and the high-purity propofovir disoproxil fumarate is prepared by taking the propofovir disoproxil fumarate as a starting material through special phosphorus chiral atom synthesis, purification and separation. The purity of the prepared propofovir disoproxil fumarate is greater than 99.90%, the diastereoisomer is less than 0.15%, the content of other single impurities is less than 0.10%, and the method has high commercialscale production value.

Preparation method of intermediate GS103 of tenofovir prodrug

The invention relates to a preparation method of an intermediate GS103 of a tenofovir prodrug. A product obtained by the method is good in purity and high in yield.